September 23, 2019
Off
Annexon Biosciences Announces FDA Fast Track Designation for Novel C1q Inhibitor ANX005 for the Treatment of Guillain-Barré Syndrome
By BusinessWire– Annexon plans to advance the clinical development of ANX005 for the treatment of GBS – SOUTH SAN FRANCISCO, Calif.–(BUSINESS…